Could the recent stagnation of the stock price be due to the FDA approval of the spot competitor which was announced last week.
I know CST say this is more of a research tool but they are likely to pick up some market share however small. Is this being factored into the Cellestis sales projections and therefore affecting stock price?
Could the recent stagnation of the stock price be due to the FDA...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
